The NEW DAY study evaluating Iluvien for diabetic macular edema did not meet its primary endpoint, but showed favorable ...

We use cookies and other tracking technologies to improve your browsing experience on our website, to show you personalized content and targeted ads, to analyze our website traffic, and to understand ...

New anti-VEGF agents for wet age-related macular degeneration can extend injection intervals to 3-5 months but may increase ...

Neovascular age-related macular degeneration (nAMD) is a progressive eye disease characterized by choroidal ...

North America leads market expansion as companies advance next-generation ophthalmic therapies to address rising prevalence ...

D Molecular Therapeutics advances 4D-150 for wet AMD and DME, revealing promising trial results and regulatory progress for ...

The agreement with Palatin follows a $1bn deal with Re-Vana earlier this year as Boehringer targets the ophthalmology market.

Iluvien for diabetic macular edema demonstrated longer-lasting intervals between injections and noninferior visual acuity ...

EyePoint Pharmaceuticals completed enrollment in the LUCIA trial, its second phase 3 trial of Duravyu in patients with wet ...

Patients with challenging diabetic macular edema may achieve anatomical gains and extended dosing intervals with bispecific faricimab.

Detailed price information for 4D Molecular Therapeutics Inc (FDMT-Q) from The Globe and Mail including charting and trades.